How much revenue did Dexcom generate this year?
Dexcom has achieved a revenue of 4.42 B USD this year.
Dexcom Revenue 2024
Dexcom Revenue
4.42 B USD
Ticker
DXCM
ISIN
US2521311074
WKN
A0D9T1
In 2024, Dexcom's sales reached 4.42 B USD, a 21.97% difference from the 3.62 B USD sales recorded in the previous year.
The Dexcom Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 9.43 | 24,45 |
| 2028e | 8.07 | 28,56 |
| 2027e | 7.07 | 32,62 |
| 2026e | 6.19 | 37,25 |
| 2025e | 5.27 | 43,78 |
| 2024e | 4.42 | 52,18 |
| 2023 | 3.62 | 63,65 |
| 2022 | 2.91 | 65,19 |
| 2021 | 2.45 | 69,78 |
| 2020 | 1.93 | 67,71 |
| 2019 | 1.48 | 64,07 |
| 2018 | 1.03 | 64,36 |
| 2017 | 0.72 | 68,49 |
| 2016 | 0.57 | 66,00 |
| 2015 | 0.4 | 69,25 |
| 2014 | 0.26 | 68,02 |
| 2013 | 0.16 | 62,56 |
| 2012 | 0.1 | 46,65 |
| 2011 | 0.08 | 46,92 |
| 2010 | 0.05 | 37,86 |
| 2009 | 0.03 | 12,46 |
| 2008 | 0.01 | -56,12 |
| 2007 | 0 | -176,09 |
| 2006 | 0 | -400,00 |
| 2005 | - | - |
| 2004 | - | - |
Dexcom Revenue, EBIT, Net Income US2521311074 · A0D9T1
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Dexcom, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dexcom from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dexcom’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Dexcom. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Dexcom’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Dexcom’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dexcom’s growth potential.
Dexcom Revenue, Profit, and EBIT History
| Date | Dexcom Revenue | Dexcom EBIT | Dexcom Net Income |
|---|---|---|---|
| 2029e | 9.43 B undefined | 0 undefined | 0 undefined |
| 2028e | 8.07 B undefined | 2.04 B undefined | 1.6 B undefined |
| 2027e | 7.07 B undefined | 1.72 B undefined | 1.37 B undefined |
| 2026e | 6.19 B undefined | 1.46 B undefined | 1.13 B undefined |
| 2025e | 5.27 B undefined | 1.16 B undefined | 917.16 M undefined |
| 2024e | 4.42 B undefined | 901.11 M undefined | 729.68 M undefined |
| 2023 | 3.62 B undefined | 614.3 M undefined | 541.5 M undefined |
| 2022 | 2.91 B undefined | 405.1 M undefined | 341.2 M undefined |
| 2021 | 2.45 B undefined | 293.9 M undefined | 216.9 M undefined |
| 2020 | 1.93 B undefined | 323.9 M undefined | 549.7 M undefined |
| 2019 | 1.48 B undefined | 156.4 M undefined | 101.1 M undefined |
| 2018 | 1.03 B undefined | -186.3 M undefined | -127.1 M undefined |
| 2017 | 718.5 M undefined | -42.5 M undefined | -50.2 M undefined |
| 2016 | 573.3 M undefined | -63.9 M undefined | -65.6 M undefined |
| 2015 | 402 M undefined | -57.1 M undefined | -57.6 M undefined |
| 2014 | 259.2 M undefined | -21.5 M undefined | -22.4 M undefined |
| 2013 | 160 M undefined | -28.9 M undefined | -29.8 M undefined |
| 2012 | 99.9 M undefined | -55.7 M undefined | -54.5 M undefined |
| 2011 | 76.3 M undefined | -44.8 M undefined | -44.7 M undefined |
| 2010 | 48.6 M undefined | -45.3 M undefined | -55.2 M undefined |
| 2009 | 29.7 M undefined | -45.8 M undefined | -53.5 M undefined |
| 2008 | 9.8 M undefined | -52.8 M undefined | -58.9 M undefined |
| 2007 | 4.6 M undefined | -46.7 M undefined | -48.5 M undefined |
| 2006 | 2.2 M undefined | -49.3 M undefined | -46.6 M undefined |
| 2005 | 0 undefined | -32.4 M undefined | -30.9 M undefined |
| 2004 | 0 undefined | -14.1 M undefined | -17.2 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -14.1 M USD | -17.2 M USD |
| 2005 | 0 USD | -32.4 M USD | -30.9 M USD |
| 2006 | 2.2 M USD | -49.3 M USD | -46.6 M USD |
| 2007 | 4.6 M USD | -46.7 M USD | -48.5 M USD |
| 2008 | 9.8 M USD | -52.8 M USD | -58.9 M USD |
| 2009 | 29.7 M USD | -45.8 M USD | -53.5 M USD |
| 2010 | 48.6 M USD | -45.3 M USD | -55.2 M USD |
| 2011 | 76.3 M USD | -44.8 M USD | -44.7 M USD |
| 2012 | 99.9 M USD | -55.7 M USD | -54.5 M USD |
| 2013 | 160 M USD | -28.9 M USD | -29.8 M USD |
| 2014 | 259.2 M USD | -21.5 M USD | -22.4 M USD |
| 2015 | 402 M USD | -57.1 M USD | -57.6 M USD |
| 2016 | 573.3 M USD | -63.9 M USD | -65.6 M USD |
| 2017 | 718.5 M USD | -42.5 M USD | -50.2 M USD |
| 2018 | 1.03 B USD | -186.3 M USD | -127.1 M USD |
| 2019 | 1.48 B USD | 156.4 M USD | 101.1 M USD |
| 2020 | 1.93 B USD | 323.9 M USD | 549.7 M USD |
| 2021 | 2.45 B USD | 293.9 M USD | 216.9 M USD |
| 2022 | 2.91 B USD | 405.1 M USD | 341.2 M USD |
| 2023 | 3.62 B USD | 614.3 M USD | 541.5 M USD |
| 2024e | 4.42 B USD | 901.11 M USD | 729.68 M USD |
| 2025e | 5.27 B USD | 1.16 B USD | 917.16 M USD |
| 2026e | 6.19 B USD | 1.46 B USD | 1.13 B USD |
| 2027e | 7.07 B USD | 1.72 B USD | 1.37 B USD |
| 2028e | 8.07 B USD | 2.04 B USD | 1.6 B USD |
| 2029e | 9.43 B USD | 0 USD | 0 USD |
Dexcom stock margins US2521311074 · A0D9T1
The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Dexcom's sales revenue. A higher gross margin percentage indicates that the Dexcom retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Dexcom's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Dexcom's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dexcom's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dexcom. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dexcom's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Dexcom Margin History
| Dexcom Gross margin | Dexcom Profit margin | Dexcom EBIT margin | Dexcom Profit margin |
|---|---|---|---|
| 2029e | 63.65 % | 0 % | 0 % |
| 2028e | 63.65 % | 25.24 % | 19.83 % |
| 2027e | 63.65 % | 24.26 % | 19.41 % |
| 2026e | 63.65 % | 23.59 % | 18.23 % |
| 2025e | 63.65 % | 22.01 % | 17.42 % |
| 2024e | 63.65 % | 20.4 % | 16.52 % |
| 2023 | 63.65 % | 16.96 % | 14.95 % |
| 2022 | 65.19 % | 13.92 % | 11.73 % |
| 2021 | 69.78 % | 12 % | 8.86 % |
| 2020 | 67.71 % | 16.81 % | 28.53 % |
| 2019 | 64.07 % | 10.6 % | 6.85 % |
| 2018 | 64.36 % | -18.06 % | -12.32 % |
| 2017 | 68.49 % | -5.92 % | -6.99 % |
| 2016 | 66 % | -11.15 % | -11.44 % |
| 2015 | 69.25 % | -14.2 % | -14.33 % |
| 2014 | 68.02 % | -8.29 % | -8.64 % |
| 2013 | 62.56 % | -18.06 % | -18.63 % |
| 2012 | 46.65 % | -55.76 % | -54.55 % |
| 2011 | 46.92 % | -58.72 % | -58.58 % |
| 2010 | 37.86 % | -93.21 % | -113.58 % |
| 2009 | 12.46 % | -154.21 % | -180.13 % |
| 2008 | -56.12 % | -538.78 % | -601.02 % |
| 2007 | -176.09 % | -1,015.22 % | -1,054.35 % |
| 2006 | -400 % | -2,240.91 % | -2,118.18 % |
| 2005 | 63.65 % | 0 % | 0 % |
| 2004 | 63.65 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 63.65 % | 0 % | 0 % |
| 2005 | 63.65 % | 0 % | 0 % |
| 2006 | -400 % | -2,240.91 % | -2,118.18 % |
| 2007 | -176.09 % | -1,015.22 % | -1,054.35 % |
| 2008 | -56.12 % | -538.78 % | -601.02 % |
| 2009 | 12.46 % | -154.21 % | -180.13 % |
| 2010 | 37.86 % | -93.21 % | -113.58 % |
| 2011 | 46.92 % | -58.72 % | -58.58 % |
| 2012 | 46.65 % | -55.76 % | -54.55 % |
| 2013 | 62.56 % | -18.06 % | -18.63 % |
| 2014 | 68.02 % | -8.29 % | -8.64 % |
| 2015 | 69.25 % | -14.2 % | -14.33 % |
| 2016 | 66 % | -11.15 % | -11.44 % |
| 2017 | 68.49 % | -5.92 % | -6.99 % |
| 2018 | 64.36 % | -18.06 % | -12.32 % |
| 2019 | 64.07 % | 10.6 % | 6.85 % |
| 2020 | 67.71 % | 16.81 % | 28.53 % |
| 2021 | 69.78 % | 12 % | 8.86 % |
| 2022 | 65.19 % | 13.92 % | 11.73 % |
| 2023 | 63.65 % | 16.96 % | 14.95 % |
| 2024e | 63.65 % | 20.4 % | 16.52 % |
| 2025e | 63.65 % | 22.01 % | 17.42 % |
| 2026e | 63.65 % | 23.59 % | 18.23 % |
| 2027e | 63.65 % | 24.26 % | 19.41 % |
| 2028e | 63.65 % | 25.24 % | 19.83 % |
| 2029e | 63.65 % | 0 % | 0 % |
Dexcom Aktienanalyse
What does Dexcom do?
Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Dexcom's Sales Figures
The sales figures of Dexcom originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Dexcom’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Dexcom's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Dexcom’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Dexcom Stock
How much was the turnover of the company Dexcom compared to the previous year?
The revenue of Dexcom has increased by 21.97% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Dexcom?
The revenue of Dexcom is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Dexcom measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Dexcom so important for investors?
The revenue of Dexcom is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Dexcom pay?
Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.
What is the dividend yield of Dexcom?
The current dividend yield of Dexcom is .
When does Dexcom pay dividends?
Dexcom pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Dexcom?
Dexcom paid dividends every year for the past 0 years.
What is the dividend of Dexcom?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Dexcom located?
Dexcom is assigned to the 'Health' sector.
Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dexcom from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.
When did Dexcom pay the last dividend?
The last dividend was paid out on 6/16/2024.
What was the dividend of Dexcom in the year 2023?
In the year 2023, Dexcom distributed 0 USD as dividends.
In which currency does Dexcom pay out the dividend?
The dividends of Dexcom are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Dexcom stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Dexcom
Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
